Crossmark

An evaluation of methods for the isolation of nontuberculous mycobacteria from patients with cystic fibrosis, bronchiectasis and patients assessed for lung transplantation

Crossref DOI link: https://doi.org/10.1186/s12890-019-0781-2

Published Online: 2019-01-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Stephenson, D.

Perry, A.

Appleby, M. R.

Lee, D.

Davison, J.

Johnston, A.

Jones, A. L.

Nelson, A.

Bourke, S. J.

Thomas, M. F.

De Soyza, A.

Lordan, J. L.

Lumb, J.

Robb, A. E.

Samuel, J. R.

Walton, K. E.

Perry, J. D. http://orcid.org/0000-0001-7225-7508
Funding

Funding for this research was provided by:

bioMerieux (N/A)
License Information

Text and Data Mining valid from 2019-01-21
More Information

Article History

Received: 15 September 2018

Accepted: 7 January 2019

First Online: 21 January 2019

Ethics approval and consent to participate

: Ethics approval and consent to participate were not required for this study as clarified by the Newcastle and North Tyneside Research Ethics Committee on condition that no additional samples were taken from patients for the purposes of this study. Culture results obtained from RGM medium were not used to inform treatment decisions.

: Not applicable.

: RGM medium is a proprietary product of bioMérieux, France (patent application: WO 2016/124863 A1). The Freeman Hospital Microbiology Department (represented here by DS, AP, MRA, DL, JL, AER, JRS, KEW and JDP) and Northumbria University (represented here by AJ, ALJ and AN) receive funding from bioMérieux for the development and evaluation of diagnostic products including culture media. The other authors have no competing interests to declare.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below